Clopidogrel and proton pump inhibitors: Can near patient testing help in the tailoring of dual antiplatelet prescription?

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 6, 2010, Pages 1422-1424

  Amoah, V ^a   Worrall, A P ^a   Smallwood, A ^a   Armesilla, A L ^b   Nevill, A M ^b   Cotton, J M ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; OMEPRAZOLE;

ACUTE CORONARY SYNDROME; CORONARY ARTERY BYPASS SURGERY; DRUG RESPONSE; HETEROZYGOTE; HUMAN; LETTER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 77954485485     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03855.x     Document Type: Letter

References (16)

1. Tablets Product Information. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Bridgewater, NJ, 2008
2. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008, 84:236-42.
3. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FKL, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008, 118:1894-909.
4. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999, 13:27-36.
5. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PM, Alessi C, Bonnet JL. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose. J Am Coll Cardiol 2009, 54:1149-53.
6. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148.e1-8.e5.
7. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006, 4:2508-9.
8. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-60.
9. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009, http://dx.doi.org/10.1016/S0140-6736(09)61525-7, published online September 1. DOI:
10. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-18.
11. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-44.
12. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009, 120:2322-9.
13. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 2005, 44:1179-89.
14. Zarowitz BJ. Clopidogrel: with or without a proton pump inhibitor. Geriatr Nurs 2009, 30:188-92.
15. Bhatt D. No CV events but significant GI benefits of PPI omeprazole. 2009, Transcatheter Cardiovascular Therapeutics. San Francisco
16. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue ML, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116:2923-32.